Your browser doesn't support javascript.
loading
Do cancer treatments have option value? Real-world evidence from metastatic melanoma.
Li, Meng; Basu, Anirban; Bennette, Caroline S; Veenstra, David L; Garrison, Louis P.
Afiliación
  • Li M; Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, Washington.
  • Basu A; Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, Washington.
  • Bennette CS; Flatiron Health, New York, New York.
  • Veenstra DL; Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, Washington.
  • Garrison LP; Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, Washington.
Health Econ ; 28(7): 855-867, 2019 07.
Article en En | MEDLINE | ID: mdl-31237095
A change in the expectations about future treatments may change the option value of a current treatment, thereby affecting its utilization. We conducted an interrupted time series analysis using a large administrative claims database to test whether the utilization of existing cancer treatments changed after the disclosures of the then-investigational drug ipilimumab's Phase II and Phase III results among metastatic melanoma patients from 2008 to 2011. We used a multinomial logistic regression to analyze the temporal probability of receiving antineoplastic systemic therapy, surgical resection of metastasis, or both, relative to no treatment, in the first 3 months following the first metastasis diagnosis. One thousand eight hundred forty-six metastatic melanoma patients were included. After adjusting for clinical and sociodemographic variables and the underlying time trend, the disclosure of ipilimumab's Phase II result was associated with a nearly twofold immediate increase in the probability of receiving surgical resection of metastasis relative to no treatment, which was significant at 5% level. No significant effect was observed for the time trend. No significant effects were found for the announcement of the Phase III result. Our findings in metastatic melanoma provide the first empirical evidence of the impact of option value in cancer treatment decision making.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toma de Decisiones / Prioridad del Paciente / Ipilimumab / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Health Econ Asunto de la revista: SERVICOS DE SAUDE Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toma de Decisiones / Prioridad del Paciente / Ipilimumab / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Health Econ Asunto de la revista: SERVICOS DE SAUDE Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido